Table 1.
Demographic and clinical characteristics in the total vaccinated cohort
| |
QIV |
TIV-Vic |
TIV-Yam |
|---|---|---|---|
| N = 3036 | N = 1010 | N = 610 | |
| Mean age, years (SD; median; range) |
57.9 (17.7; 64.0; 18.0–92.0) |
58.1 (17.8; 64.0; 18.0–92.0) |
58.1 (17.9; 65.0; 18.0–90.0) |
| Sub-groups: mean age, years (SD, median) |
43.5 (13.58; 44.0) |
43.7 (13.84; 44.0) |
43.5 (14.01; 46.0) |
| 18–64 years |
72.3 (5.45; 71.0) |
72.5 (5.53; 71.0) |
72.4 (5.39; 72.0) |
| ≥65 years |
|
|
|
| Male, n (%) |
1291 (42.5) |
462 (45.7) |
267 (43.8) |
| Hispanic/Latino ethnicity, n (%) |
134 (4.4) |
47 (4.7) |
25 (4.1) |
| Not Hispanic/Latino ethnicity, n (%) |
2902 (95.6) |
963 (95.3) |
585 (95.9) |
| Geographic ancestry |
2078 (68.4) |
699 (69.2) |
414 (67.9) |
| European heritage / Caucasian |
22 (0.7) |
7 (0.7) |
4 (0.7) |
| Arabic/north American heritage / Caucasian |
805 (26.5) |
270 (26.7) |
162 (26.5) |
| Asian |
106 (3.5) |
26 (2.6) |
21 (3.4) |
| African heritage / African American |
6 (0.2) |
2 (0.2) |
3 (0.5) |
| American Indian or native Alaskan |
2 (0.1) |
0 |
0 |
| Native Hawaiian or other pacific islander |
17 (0.6) |
6 (0.6) |
6 (1.0) |
| Other |
|
|
|
| Medical history, n (%) |
533 (17.56) |
153 (15.15) |
106 (17.38) |
| Cardiovascular disease† |
457 (15.05) |
129 (12.77) |
89 (14.59) |
| Diabetes |
293 (9.65) |
104 (10.30) |
57 (9.34) |
| Chronic respiratory disease |
117 (3.85) |
39 (3.86) |
26 (4.26) |
| Cancer |
76 (2.50) |
17 (1.68) |
13 (2.13) |
| Cerebrovascular disease |
60 (1.98) |
23 (2.28) |
13 (2.13) |
| Chronic hepatic disease |
43 (1.42) |
11 (1.09) |
6 (0.98) |
| Chronic renal disease |
|
|
|
| Received seasonal influenza vaccination in at least one of previous three seasons, n (%) |
2395 (78.9) |
788 (78.0) |
483 (79.2) |
| Received A/H1N1pdm09 vaccination during the previous season | 848 (27.9) | 289 (28.6) | 165 (27.0) |
QIV inactivated quadrivalent influenza vaccine, SD standard deviation, TIV-Vic inactivated trivalent influenza vaccine Victoria lineage B strain, TIV-Yam inactivated trivalent influenza vaccine Yamagata lineage B strain, †Excluding hypertension.